A randomized, placebo-controlled, dose-escalation phase I/II multicenter trial of low-dose cidofovir for BK polyomavirus nephropathy.

Hannah ImlayJohn W GnannJames RooneyV Ram PeddiAlexander C WisemanMichelle A JosephsonClifton KewJo-Anne H YoungDeborah B AdeyMilagros Samaniego-PicotaRichard J WhitleyAjit P Limaye

Published in: Transplant infectious disease : an official journal of the Transplantation Society (2024)

These preliminary results indicate that low-dose cidofovir was safe and tolerated but had no significant BKPyV-specific antiviral effect in KTRs with BKPyVAN.

Keyphrases

low dose
double blind
placebo controlled
phase iii
phase ii
study protocol
high dose
open label
clinical trial
randomized controlled trial
cross sectional
phase ii study
squamous cell carcinoma